Galectin Therapeutics Inc. (GALT)

Market Cap	123.70M
Revenue (ttm)	n/a
Net Income (ttm)	-45.44M
Shares Out	61.85M
EPS (ttm)	-0.76
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	63,714
Open	1.97
Previous Close	1.95
Day's Range	1.94 - 2.06
52-Week Range	1.02 - 2.47
Beta	1.17
Analysts	Strong Buy
Price Target	11.00 (+450.0%)
Earnings Date	Nov 13, 2023

About GALT

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. The company, through its Galectin Sciences, LLC, which is...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 12
• Stock Exchange: NASDAQ
• Ticker Symbol: GALT

Analyst Forecast

According to one analyst, the rating for GALT stock is "Strong Buy" and the 12-month stock price forecast is $11.0.

Price Target

$11.0

(450.00% upside)

Analyst Consensus: Strong Buy